Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's disease
Biotech
Biogen’s tau drug drives bigger benefits in Alzheimer’s update
Biogen saw a further slowing of clinical decline after two years, leading analysts to hail the strengthening of evidence for late-phase development.
Nick Paul Taylor
Nov 18, 2026 9:26am
Priavoid’s Alzheimer’s pill fails to prove efficacy in ph. 2
Nov 18, 2026 4:21am
Cognito phase 3 flops in AD trial, but sees ‘signal’ for HOPE
Nov 18, 2026 3:23am
Fierce Pharma
AriBio’s oral Alzheimer’s drug meets monotherapy goal in ph. 3
Nov 17, 2026 7:43am
Lilly scraps ph. 2 Alzheimer's program after drug falls short
Oct 29, 2026 2:09pm
Acadia misses mark in Alzheimer’s but continues phase 3 program
Sep 24, 2026 9:46am